Donald Trump's firm launches new America-made smartphone Trump Mobile for $499 — Check monthly subscription costs
US President Donald Trump's company, Trump Organization, launched an America-made smartphone named Trump Mobile on Monday, 16 June 2025, according to the news agency Reuters. The company aims to capture conservative consumers and give them an alternative to other major telecom providers.
This is a developing story. Please check back for updates.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
36 minutes ago
- Time of India
US pharma bets big on China to snap up potential blockbuster drugs
U.S. drugmakers are increasingly licensing drug candidates from Chinese biotech firms, with 14 such deals worth up to $18.3 billion signed in 2025 so far—up from just two in the same period last year, according to GlobalData. This surge is driven by the need to replace $200 billion worth of medicines set to lose patent protection by 2030. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads ( Originally published on Jun 16, 2025 ) U.S. drugmakers are licensing molecules from China for potential new medicines at an accelerating pace, according to new data, betting they can turn upfront payments of as little as $80 million into multibillion-dollar June, U.S. drugmakers have signed 14 deals potentially worth $18.3 billion to license drugs from China-based companies. That compares with just two such deals in the year-earlier period, according to data from GlobalData provided exclusively to increased pace is expected to continue as U.S. drugmakers look to rebuild pipelines of future products to replace $200 billion worth of medicines that will lose patent protection by the end of the decade, analysts, investors, a banker and a drug company executive told Reuters."They are finding very high-quality assets coming out of China and at prices that are much more affordable relative to perhaps the equivalent type of product that they might find in the United States," said Mizuho analyst Graig total cost of licensing agreements, including low upfront payments and subsequent larger payouts, averaged $84.8 billion in the U.S., compared with $31.3 billion in China over the past five years, according to GlobalData.A licensing agreement grants a company the rights to develop, manufacture, and commercialize another company's pharmaceutical products or technologies in exchange for future target-based, or "milestone", payments while mitigating development share of global drug development is now nearly 30%, while the U.S. share of the world's research and development has slipped 1% to about 48%, according to pharmaceutical data provider Citeline's report in companies have licensed experimental drugs to U.S. drugmakers that could be used for obesity, heart disease and cancer, reflecting abundant Chinese government investment in pharmaceutical and biotech research and small molecules, like oral drugs, have been the most commonly licensed, there has been a notable shift toward novel treatments such as targeted cancer therapies and first-in-class medicines, Jefferies analysts said in a note in May. Chinese biotechs are moving up the value chain by the day. They are... challenging their Western peers," said Macquarie Capital analyst Tony growth is happening even as the U.S. and China have wrangled over tariffs and U.S. President Donald Trump pushes a made in America has cut into traditional mergers and acquisitions, which are down 20%, with only 50 such transactions so far this year, according to data from a third of the assets that large pharmaceutical companies licensed in 2024 were from China, said Brian Gleason, head of biotech investment banking at Raymond James, who estimated such licensing deals would increase to between 40% and 50%."I think it's only accelerating," Gleason Trump administration is currently doing a national security investigation as it weighs if it will impose tariffs on the pharmaceutical one healthcare analyst said licensing deals should continue because the yet to be marketed products are not impacted by tariffs."The law that gives the president the right to impose tariffs applies to goods. It explicitly excludes intellectual property," said Tim Opler, managing director in Stifel's global healthcare May, Pfizer spent $1.25 billion upfront for the right to license an experimental cancer drug from China's 3SBio . That is the largest such deal this year and could be worth up to $6 billion in payments to 3SBio if the drug is Pharmaceuticals in June paid $80 million upfront in a potential $2 billion deal for an experimental obesity drug from China's Hansoh Pharmaceuticals.'WAKEUP CALL'By licensing a drug in development, U.S. and European drugmakers get very quick access to a molecule which would take them longer and cost more to discover or design themselves, analysts say.U.S.-based drug developer Nuvation Bio bought AnHeart Therapeutics in 2024, gaining access to the China-based company's experimental cancer drug taletrectinib, which received U.S. approval last week."We consider our presence in China not only a great avenue for R&D, but we also view it as an inside track on obtaining further assets to grow our company further and find new and better therapies to offer patients," Nuvation CEO David Hung told makes China attractive, said EY analyst Arda Ural, "a fraction of the cost and then multiples of time."Analysts have pointed to large drugmakers strategically securing rights to drugs at lower cost and running efficient early-stage trials in China to obtain important data, paving the way for global trials and potential earlier market entry."It's a little bit of a wakeup call to our industry," said Chen Yu, Managing Partner at U.S.-based healthcare investment firm TCGX.
Hindustan Times
43 minutes ago
- Hindustan Times
Trump Mobile's T1 phone: How much will the gold smartphone cost and how to pre-order now?
The Trump family on Monday said it is starting a new mobile phone service. The president's son, Eric, said that the new venture is called Trump Mobile and it will sell phones that will be built in the US. He further announced a new mobile phone and service, called T1 Phone, which will be gold and is 'proudly designed and built in the United States'. The T1 Phone is currently available for pre-order, per the Trump Mobile website. The phone will be available in September. Customers can also subscribe to 'Trump Mobile' with their current mobile device. Read More: Trump Mobile released, T1 phone to be launched Sept 2025 | What do they offer? 'Hard-working Americans deserve a wireless service that's affordable, reflects their values, and delivers reliable quality they can count on,' Eric Trump said in a statement on Monday. The Trump Organization said the new, gold-coloured phone available for USD 499 in August, called the T1 Phone, won't be designed or made by Trump Mobile, but by another company. Retail Price: The T1 Phone is priced at $499. A $100 deposit is required for pre-orders. Service Plan: The accompanying '47 Plan' costs $47.45/month, offering unlimited talk, text, and data, plus extras like telehealth and roadside assistance. Announced Release: Trump Mobile's press release states the T1 Phone will launch in August 2025, but the official website lists September 2025. Pre-Order Status: Pre-orders are open as of June 16, 2025, with a $100 deposit. Read More: Trump Mobile copying Obama's phone strategy? Here's how the two plans are different The T1 runs Android 15 with a 6.8-inch AMOLED display (120Hz), 50MP main camera, 12GB RAM, 256GB expandable storage, 5,000mAh battery, and features like a headphone jack and AI Face Unlock. However, the chipset is unspecified, and the camera quality is questioned. A 250-seat customer service center will be set up in the US to assist subscribers. Customers will be able to switch to the Trump Mobile network with their current phones,or connect with the new Android-based T1.
Time of India
an hour ago
- Time of India
Israel-Iran war: Netanyahu says eliminating Khamenei would end crisis, 'We are fighting your enemy'
Israeli Prime Minister Benjamin Netanyahu says eliminating Khamenei would end the crisis. A day after it was reported that US president Donald Trump blocked an Israeli plan to kill Iran Supreme Leader Ayatollah Ali Khamenei, Israel PM Benjamin Netanyahu said Israel is not ruling out eliminating Khamenei as that would only end the 'forever war' that Iran wants. Speaking to ABC News, Netanyahu said it (killing Khamenei) would not going to escalate the conflict. Israel was going what is needed to be done, Netanyahu said. "We've had half a century of conflict spread by this regime that terrorizes everyone in the Middle East; has bombed the Aramco oil fields in Saudi Arabia; is spreading terrorism and subversion and sabotage everywhere," Netanyahu said. "The 'forever war' is what Iran wants, and they're bringing us to the brink of nuclear war. In fact, what Israel is doing is preventing this, bringing an end to this aggression, and we can only do so by standing up to the forces of evil. " 'It's basically Hitler's nuclear team' Netanyahu said Israel targeted Iran's top nuclear scientists which is basically like Hitler's nuclear team. "Today, it's Tel Aviv. Tomorrow, it's New York. Look, I understand 'America First'. I don't understand 'America Dead'. That's what these people want. They chant 'Death to America.' by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like These Companies Are Overcharging You for Ohio Auto Insurance Smart Lifestyle Trends Learn More Undo So we're doing something that is in the service of mankind, of humanity, and it's a battle of good against evil. America does, should, and does stand with the good. That's what President Trump is doing, And I deeply appreciate his support," Netanyahu said. US' role and prior knowledge about Israel's attack on Iran has emerged as a contentious issue as Trump claimed that he knew about the attack but now wants Israel and Iran to talk immediately about de-escalation. Netanyahu says Israel is fighting US' war Netanyahu said it's not only Israel's fight, it's also US's fight. "For God's sake, they chant, 'death to Israel, death to America.' We're simply on their way. And this could reach America soon," Netanyahu said. "We're taking the action. America is supporting us in defense. Deeply, deeply appreciated. But this is a threat to the entire world," Netanyahu said. "It's a threat to Israel; as I said -- to our Arab neighbors; to Europe; to America. They chant 'Death to America.' It's though -- 'This is not your business'? This is not myopia. This is utter blindness." "Sometimes you have to take a stand against evil. And that's what the American people instinctively understand. Most of them, I have to say. And that's what President Trump understands. We cannot let that happen," he added.
